Facility Intensification and Cost Reduction using an Integrated Buffer Delivery Platform

Proteolysis-targeting chimeras (PROTACs) are a class of bifunctional molecules which are enabling the development of drugs against targets once considered inaccessible.

The discovery and development of immune checkpoint inhibitors has revolutionized the treatment of certain cancers, with the 2018 Nobel Prize in medicine/physiology recognizing these therapies as a "landmark in our fight against cancer." Yet, despite these advances, putative biomarker identification, efficacy, and drug resistance still pose significant therapeutic challenges. In this webinar, leaders in immuno-oncology — Elaine Mardis (The Ohio State University) and Jedd Wolchok (Memorial Sloan Kettering Cancer Center) — survey the landscape of research, revealing new approaches for harnessing the potential of this transformative therapeutic.

Genome-scale CRISPR screens in cancer cell lines have enabled the unprecedented identification of genome-scale vulnerabilities and co-dependencies. However, a significant obstacle in identifying co-dependencies is that the range of genomic features defines the discovery space. Therefore, it is clear that paired perturbations are needed to comprehensively map co-dependencies and establish functional genetic interaction maps.

Mixed Reality (MR) also known as “hybrid reality” and “extended reality,” has the potential to change just about every industry, healthcare being no exception. A combination of Virtual Reality (VR), Augmented Reality (AR), and Artificial Intelligence (AI); MR is emerging as a tech to create experiences that blend the real-life environment with digital elements.